Marksans Pharma Ltd
MARKSANSMarksans Pharma Ltd
MARKSANS![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/smallcap.png)
![](https://assets.tickertape.in/sector-icons/high_risk.png)
Price Chart
Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
31.77 | 6.01 | 0.26% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 2 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 902.20 | 774.18 | 921.16 | 1,004.69 | 1,134.54 | 1,382.87 | 1,532.69 | 1,911.45 | 2,227.83 | 2,323.27 | ||||||||||
Raw Materials | 504.85 | 506.68 | 502.58 | 517.91 | 514.88 | 731.33 | 703.92 | 927.75 | 1,718.83 | 1,782.95 | ||||||||||
Power & Fuel Cost | 12.58 | 12.97 | 11.55 | 13.99 | 14.00 | 16.42 | 18.59 | 24.50 | ||||||||||||
Employee Cost | 122.42 | 149.70 | 147.75 | 159.07 | 168.42 | 197.32 | 220.30 | 239.37 | ||||||||||||
Selling & Administrative Expenses | 65.78 | 65.18 | 88.83 | 109.58 | 120.38 | 154.55 | 148.41 | 144.74 | ||||||||||||
Operating & Other expenses | 51.43 | -12.12 | 83.60 | 67.38 | 124.28 | -63.05 | 140.74 | 176.46 | ||||||||||||
EBITDA | 145.14 | 51.77 | 86.85 | 136.76 | 192.58 | 346.30 | 300.73 | 398.63 | 509.00 | 540.32 | ||||||||||
Depreciation/Amortization | 28.13 | 30.09 | 26.84 | 22.80 | 26.66 | 36.15 | 44.78 | 51.85 | 74.27 | 81.05 | ||||||||||
PBIT | 117.01 | 21.68 | 60.01 | 113.96 | 165.92 | 310.15 | 255.95 | 346.78 | 434.73 | 459.27 | ||||||||||
Interest & Other Items | 10.16 | 6.78 | 10.22 | 9.66 | 8.75 | 7.99 | 8.45 | 9.13 | 11.20 | 12.55 | ||||||||||
PBT | 106.85 | 14.90 | 49.79 | 104.30 | 157.17 | 302.16 | 247.50 | 337.65 | 423.53 | 446.72 | ||||||||||
Taxes & Other Items | 28.33 | 6.06 | 16.86 | 27.84 | 36.42 | 66.22 | 62.95 | 71.34 | 109.83 | 112.92 | ||||||||||
Net Income | 78.52 | 8.84 | 32.93 | 76.46 | 120.75 | 235.94 | 184.55 | 266.31 | 313.70 | 333.80 | ||||||||||
EPS | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 6.18 | 6.92 | 7.37 | ||||||||||
DPS | 0.41 | 0.05 | 0.05 | 0.05 | 0.10 | 0.25 | 0.25 | 0.50 | 0.60 | 0.00 | ||||||||||
Payout ratio | 0.21 | 0.23 | 0.06 | 0.03 | 0.03 | 0.04 | 0.06 | 0.08 | 0.09 | 0.00 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Marksans Pharma Ltd | 33.81 | 6.01 | 0.26% |
Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
Cipla Ltd | 31.71 | 4.88 | 0.80% |
Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare MARKSANS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 1.46%
Increased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has increased by 3.02%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Decreased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has decreased by 1.41%
Top 5 Mutual Funds holding Marksans Pharma Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Kotak Special Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5550% | Percentage of the fund’s portfolio invested in the stock 2.50% | Change in the portfolio weight of the stock over the last 3 months 2.50% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 18/35 (+1) |
UTI Small Cap Fund - Direct Growth Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5323% | Percentage of the fund’s portfolio invested in the stock 1.34% | Change in the portfolio weight of the stock over the last 3 months 0.25% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 62/98 (+5) |
UTI Aggressive Hybrid Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4700% | Percentage of the fund’s portfolio invested in the stock 0.82% | Change in the portfolio weight of the stock over the last 3 months 0.07% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 71/113 (-4) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividend Cuts
MARKSANS has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.26%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.56 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
Cash Dividend
Ex DateEx DateSep 17, 2024
Dividend/Share
₹0.60
Ex DateEx Date
Sep 17, 2024
Past Dividends
Cash Dividend
Ex DateEx DateJun 7, 2023
Dividend/Share
₹0.50
Ex DateEx Date
Jun 7, 2023
Cash Dividend
Ex DateEx DateAug 19, 2022
Dividend/Share
₹0.25
Ex DateEx Date
Aug 19, 2022
Cash Dividend
Ex DateEx DateSep 15, 2021
Dividend/Share
₹0.25
Ex DateEx Date
Sep 15, 2021
Cash Dividend
Ex DateEx DateSep 22, 2020
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
The inspection has been classified as voluntary action indicated (VAI) and has been closed accordingly, the firm added. Earlier, on 18 April 2024, the USFDA conducted good manufacturing practices (GMP) inspection at the company's facility located at Verna Industrial estate, Verna, Goa, India and issued five inspectional observations in Form 483. The inspection was conducted from 9 April to 17 April 2024. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The pharma company reported 29.27% increase in consolidated net profit to Rs 88.75 crore in Q1 FY25 from Rs 68.66 crore in Q1 FY24. Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25. The scrip rose 0.36% to Rs 221.30 on the BSE.Powered by Capital Market - Live
Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Verna, Goa and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI).Powered by Capital Market - Live
Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live
Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25, driven by new launches and increase in our share with existing customers in the key markets. Research & Development (R&D) spend stood at Rs 12 crore during the quarter, 2% of consolidated revenue. Profit before tax rose 23.95% to Rs 120.02 crore in June 2024 quarter as compared with Rs 96.83 crore posted in corresponding quarter previous fiscal. EBITDA climbed 26% to Rs 128.4 crore in Q1 FY25 as compared to Rs 102 crore in same period last year. EBITDA margin improved to 21.7% in Q1 of FY25 as compared to 20.4% in the corresponding period last year. During the quarter, revenue from US & North America stood at Rs 250.9 crore (up 29.8% YoY) and UK and Europe stood at Rs 251.5 crore (up 11.3% YoY). Revenue from Australia and New Zealand business stood at Rs 65.6 crore (down 12% YoY) in Q1 FY24. Rest of World (ROW) business grew by 2.1% YoY to Rs 22.7 crore during the period under review. In Q1 FY25, the capex incurred was Rs 31 crore, which is in line with the firm's plan for scaling the acquired manufacturing unit from Teva Pharma in Goa. The cash balance at the end of 30 June 2024 is at Rs 691 crore. In Q1 FY25, cash from operations was at Rs 45.3 crore and free cash flow was at 14.3 crore. The pharmaco received market authorization from UKMHRA for products Levonorgestrel 1.5mg tablets, Rasagiline 1mg tablets and Olmesartan 10, 20, 40mg tablets during the period under review. Mark Saldanha, managing director, Marksans Pharma, said, We are delighted to build on the growth momentum from the last year ' the first quarter of FY25 has shown strong start with 18% YoY increase in revenue and 26% YoY increase in EBITDA. The growth is supported by increase in share from existing customers and new launches. We experienced favorable raw material prices, however surge in freight costs continue. The shipments from the new facility have commenced to our key markets, and with that we remain optimistic for a stronger performance in the coming quarters, and our journey towards achieving the next revenue goal of Rs. 3,000 crores over the next two years.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. Powered by Capital Market - Live
Net profit of Marksans Pharma rose 29.26% to Rs 88.75 crore in the quarter ended June 2024 as against Rs 68.66 crore during the previous quarter ended June 2023. Sales rose 18.12% to Rs 590.62 crore in the quarter ended June 2024 as against Rs 500.03 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales590.62500.03 18 OPM %21.7520.39 - PBDT140.46110.49 27 PBT120.0296.83 24 NP88.7568.66 29 Powered by Capital Market - Live
Marksans Pharma announced that its wholly owned subsidiary Relonchem has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA. Levonorgestrel, also known as the morning-after pill, is a first-line oral emergency contraceptive pill. It is to be used within 72 hours of unprotected sexual intercourse or when a presumed contraceptive failure has occurredPowered by Capital Market - Live
Marksans Pharma will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Raymond Ltd leads gainers in ‘A’ group
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
![](https://i4.ytimg.com/vi/wN2jpm9O0LU/hqdefault.jpg)
![](https://i3.ytimg.com/vi/vxJG-XAXNc8/hqdefault.jpg)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.27%, vs industry avg of 9.21%
Increasing Market Share
Over the last 5 years, market share increased from 0.44% to 0.59%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 32.62%, vs industry avg of 15.17%